These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

420 related items for PubMed ID: 15799128

  • 1. Testosterone therapy--what, when and to whom?
    Jockenhövel F.
    Aging Male; 2004 Dec; 7(4):319-24. PubMed ID: 15799128
    [Abstract] [Full Text] [Related]

  • 2. Testosterone supplementation: what and how to give.
    Jockenhövel F.
    Aging Male; 2003 Sep; 6(3):200-6. PubMed ID: 14628500
    [Abstract] [Full Text] [Related]

  • 3. A pharmacokinetic study of injectable testosterone undecanoate in hypogonadal men.
    Zhang GY, Gu YQ, Wang XH, Cui YG, Bremner WJ.
    J Androl; 1998 Sep; 19(6):761-8. PubMed ID: 9876028
    [Abstract] [Full Text] [Related]

  • 4. Nebido: a long-acting injectable testosterone for the treatment of male hypogonadism.
    Harle L, Basaria S, Dobs AS.
    Expert Opin Pharmacother; 2005 Aug; 6(10):1751-9. PubMed ID: 16086661
    [Abstract] [Full Text] [Related]

  • 5. The role of long-acting parenteral testosterone undecanoate compound in the induction of secondary sexual characteristics in males with hypogonadotropic hypogonadism.
    Giagulli VA, Triggiani V, Carbone MD, Corona G, Tafaro E, Licchelli B, Guastamacchia E.
    J Sex Med; 2011 Dec; 8(12):3471-8. PubMed ID: 21995803
    [Abstract] [Full Text] [Related]

  • 6. The response to testosterone undecanoate in men with type 2 diabetes is dependent on achieving threshold serum levels (the BLAST study).
    Hackett G, Cole N, Bhartia M, Kennedy D, Raju J, Wilkinson P, Saghir A, Blast Study Group.
    Int J Clin Pract; 2014 Feb; 68(2):203-15. PubMed ID: 24355040
    [Abstract] [Full Text] [Related]

  • 7. Evidence-based medicine update on testosterone replacement therapy (TRT) in male hypogonadism: focus on new formulations.
    Giagulli VA, Triggiani V, Corona G, Carbone D, Licchelli B, Tafaro E, Resta F, Sabbà C, Maggi M, Guastamacchia E.
    Curr Pharm Des; 2011 Feb; 17(15):1500-11. PubMed ID: 21521164
    [Abstract] [Full Text] [Related]

  • 8. Androgen substitution with testosterone undecanoate in survivors of bilateral testicular cancer requires individually-adjusted injection intervals.
    Brabrand S, Fosså SD, Cvancarova M, Lehne G.
    BJU Int; 2011 Apr; 107(7):1080-7. PubMed ID: 20825398
    [Abstract] [Full Text] [Related]

  • 9. Male hypogonadism : an update on diagnosis and treatment.
    Darby E, Anawalt BD.
    Treat Endocrinol; 2005 Apr; 4(5):293-309. PubMed ID: 16185098
    [Abstract] [Full Text] [Related]

  • 10. Current topics in testosterone replacement of hypogonadal men.
    Nieschlag E.
    Best Pract Res Clin Endocrinol Metab; 2015 Jan; 29(1):77-90. PubMed ID: 25617174
    [Abstract] [Full Text] [Related]

  • 11. Review of Testim gel.
    McNicholas T, Ong T.
    Expert Opin Pharmacother; 2006 Mar; 7(4):477-84. PubMed ID: 16503819
    [Abstract] [Full Text] [Related]

  • 12. Androgen replacement therapy: present and future.
    Gooren LJ, Bunck MC.
    Drugs; 2004 Mar; 64(17):1861-91. PubMed ID: 15329035
    [Abstract] [Full Text] [Related]

  • 13. Intramuscular testosterone undecanoate: pharmacokinetic aspects of a novel testosterone formulation during long-term treatment of men with hypogonadism.
    Schubert M, Minnemann T, Hübler D, Rouskova D, Christoph A, Oettel M, Ernst M, Mellinger U, Krone W, Jockenhövel F.
    J Clin Endocrinol Metab; 2004 Nov; 89(11):5429-34. PubMed ID: 15531493
    [Abstract] [Full Text] [Related]

  • 14. Unexpectedly prolonged washout period of exogenous testosterone after discontinuation of intramuscular testosterone undecanoate depot injection (Nebido(®) or Reandron(®) ) in men with congenital hypogonadotrophic hypogonadism.
    Gan EH, Bouloux PM, Quinton R.
    Clin Endocrinol (Oxf); 2016 Jun; 84(6):947-50. PubMed ID: 26732131
    [No Abstract] [Full Text] [Related]

  • 15. [What is the interest of Klinefelter's syndrome for (child) psychiatrists?].
    Kebers F, Janvier S, Colin A, Legros JJ, Ansseau M.
    Encephale; 2002 Jun; 28(3 Pt 1):260-5. PubMed ID: 12091788
    [Abstract] [Full Text] [Related]

  • 16. Testosterone undecanoate in the treatment of male hypogonadism.
    Edelstein D, Basaria S.
    Expert Opin Pharmacother; 2010 Aug; 11(12):2095-106. PubMed ID: 20642374
    [Abstract] [Full Text] [Related]

  • 17. Testosterone treatment comes of age: new options for hypogonadal men.
    Nieschlag E.
    Clin Endocrinol (Oxf); 2006 Sep; 65(3):275-81. PubMed ID: 16918944
    [Abstract] [Full Text] [Related]

  • 18. Repeated intramuscular injections of testosterone undecanoate for substitution therapy in hypogonadal men.
    Nieschlag E, Büchter D, Von Eckardstein S, Abshagen K, Simoni M, Behre HM.
    Clin Endocrinol (Oxf); 1999 Dec; 51(6):757-63. PubMed ID: 10619981
    [Abstract] [Full Text] [Related]

  • 19. The HEAT-Registry (HEmatopoietic Affection by Testosterone): comparison of a transdermal gel vs long-acting intramuscular testosterone undecanoate in hypogonadal men.
    Zitzmann M, Cremers JF, Krallmann C, Kliesch S.
    Aging Male; 2022 Dec; 25(1):134-144. PubMed ID: 35467476
    [Abstract] [Full Text] [Related]

  • 20. Hypotestosteronaemia in the aging male: should we treat it?
    Christe N, Meier CA.
    Swiss Med Wkly; 2015 Dec; 145():w14216. PubMed ID: 26599486
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.